References:
1. Crombie JL, LaCasce AS. Epstein Barr Virus Associated B-Cell
Lymphomas and Iatrogenic Lymphoproliferative Disorders. Front Oncol
2019;9:109.
2. Fauci AS, Haynes BF, Costa J, Katz P, Wolff SM. Lymphomatoid
Granulomatosis. Prospective clinical and therapeutic experience over 10
years. N Engl J Med 1982;306:68-74.
3. Katzenstein AL, Doxtader E, Narendra S. Lymphomatoid granulomatosis:
insights gained over 4 decades. Am J Surg Pathol 2010;34:e35-48.
4. Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis.
Hum Pathol 1972;3:457-558.
5. Melani C, Jaffe ES, Wilson WH. Pathobiology and treatment of
lymphomatoid granulomatosis, a rare EBV-driven disorder. Blood
2020;135:1344-52.
6. Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of
lymphomatoid granulomatosis with Epstein-Barr viral infection of B
lymphocytes and response to interferon-alpha 2b. Blood 1996;87:4531-7.
7. Sebire NJ, Haselden S, Malone M, Davies EG, Ramsay AD. Isolated EBV
lymphoproliferative disease in a child with Wiskott-Aldrich syndrome
manifesting as cutaneous lymphomatoid granulomatosis and responsive to
anti-CD20 immunotherapy. J Clin Pathol 2003;56:555-7.
8. Benouaich-Amiel A Y-KS, Fichman S, Siegal T. Lymphomatoid
granulomatosis of the central nervous system successfully treated with
corticosteroid alone: a case report and review of the literature.
Neurosurg Cases Rev 2018;1:009.
9. Lucantoni C, De Bonis P, Doglietto F, et al. Primary cerebral
lymphomatoid granulomatosis: report of four cases and literature review.
J Neurooncol 2009;94:235-42.
10. Zaidi A, Kampalath B, Peltier WL, Vesole DH. Successful treatment of
systemic and central nervous system lymphomatoid granulomatosis with
rituximab. Leuk Lymphoma 2004;45:777-80.
11. Knoops L, Haas R, de Kemp S, et al. In vivo p53 response and immune
reaction underlie highly effective low-dose radiotherapy in follicular
lymphoma. Blood 2007;110:1116-22.
12. Skvortsova I, Skvortsov S, Popper BA, et al. Rituximab enhances
radiation-triggered apoptosis in non-Hodgkin’s lymphoma cells via
caspase-dependent and - independent mechanisms. J Radiat Res
2006;47:183-96.
13. Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K. Treatment of
limited stage follicular lymphoma with Rituximab immunotherapy and
involved field radiotherapy in a prospective multicenter Phase II
trial-MIR trial. BMC Cancer 2011;11:87.
14. Brocklehurst S DN, Shah JL, Rizvi S, Ramakrishnan Geethakumari P,
Kumar K. Combined Modality Low-Dose Radiation Therapy (2 Gy x 2) and
Single-Agent Rituximab Immunotherapy in the Treatment of Indolent
Non-Hodgkin Lymphoma. Blood 2019;134:5262.
15. Bollard CM, Gottschalk S, Torrano V, et al. Sustained complete
responses in patients with lymphoma receiving autologous cytotoxic T
lymphocytes targeting Epstein-Barr virus latent membrane proteins. J
Clin Oncol 2014;32:798-808.